At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Dabigatran +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Dabigatran and Selpercatinib for Healthy. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participants. This study will last approximately 22 to 25 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMar 2021
Primary CompletionMay 2021
TodayJul 2026
First PostedMar 4, 2021
Enrollment StartMar 5, 2021
Primary CompletionMay 17, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.3 years ago
Interventions
Dabigatrandrug
Administered orally.
Selpercatinibdrug
Administered orally.